StockData

Xencor vs Zymeworks

XNCR and ZYME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How XNCR and ZYME compare

Xencor is the larger company, worth 1.4 times as much as Zymeworks ($2.6B against $1.8B).

Xencor grew revenue faster over the last twelve months (−28.6% versus −69.8% for Zymeworks).

Xencor keeps more of each dollar of sales as profit, with a net margin of −156% compared with −404% at Zymeworks.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricXNCRZYME
Size and price
Market cap$2.6B$1.8B
Share price$34.50$25.84
Change, 1 year131%39.5%
Change, 5 years−2.7%32.5%
Beta (5Y)−0.050.31
Employees260264
StockData Score
Total score55
Valuation score00
Growth score1 (better)0
Performance score1 (better)0
Health score35 (better)
Dividend score00
Valuation
P/S24.4× (better)49.4×
P/B5.1× (better)22.8×
FCF yield−8.1%−6.6% (better)
Fair value$11.73$3.37
Margin of safety−194% (better)−667%
Growth
Revenue growth (TTM)−28.6% (better)−69.8%
Revenue growth, 5Y average0.47%22.2% (better)
Profitability
Operating margin−206% (better)−419%
Net margin−156% (better)−404%
FCF margin−198% (better)−325%
Return on equity−29.1% (better)−72.3%
Return on invested capital−26.6% (better)−179%
Financial health
Debt / equity0.21 (better)0.00
Interest coverage−8.0×–
Current ratio6.39 (better)6.32
Altman Z-score5.01 (better)−1.10
Piotroski F-score36 (better)
Dividends and buybacks
Buyback yield–9.3%
Shareholder yield0.00%9.3% (better)
Ownership
Held by institutions113%98.1%
Held by insiders1.6%58.9%
Insider net buying, 12 months−$7.5M−$6.1M (better)
Short interest, % of float17.6%20.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.